Zoetis Inc. $ZTS Shares Acquired by Scott & Selber Inc.

Scott & Selber Inc. grew its position in Zoetis Inc. (NYSE:ZTS) by 95.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,341 shares of the company’s stock after acquiring an additional 10,884 shares during the quarter. Scott & Selber Inc.’s holdings in Zoetis were worth $2,811,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Empowered Funds LLC raised its position in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC boosted its position in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Magnetar Financial LLC acquired a new position in Zoetis during the second quarter worth about $534,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of ZTS stock opened at $115.31 on Tuesday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The company has a market capitalization of $48.68 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.77 and a beta of 0.95. The firm’s 50-day moving average is $124.15 and its two-hundred day moving average is $130.02. Zoetis Inc. has a 12 month low of $114.36 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

A number of analysts have commented on ZTS shares. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.